Moderna’s RSV Price Gamble: Doubling Down on mRNA as Rivals Dominate Market

Moderna (MRNA) and Merck (MRK) announced positive Phase 3 trial results for their personalized mRNA cancer vaccine, Intismeran Autogene, combined with Keytruda. The treatment extended survival without melanoma recurrence. MRNA stock surged 177%, MRK rose 12%. The vaccine's personalized nature and high cost may pose insurance coverage challenges. FDA approval is expected in 2027-2028. The treatment is not yet commercially priced, with estimates exceeding $150,000 per patient.

Target reported Q2 earnings with a 5.3% sales increase and 3.8% same-store sales growth, driven by a $994M tariff refund and 20% fundamental EPS growth. The company is focusing on digital sales and price cuts to attract budget-conscious shoppers. Moderna's stock surged 135% following positive Phase 3 trial results for its mRNA-based personalized cancer vaccine, a significant milestone in cancer treatment.

The FDA approved Moderna's mRNA flu vaccine, citing 26.6% higher efficacy than traditional vaccines. However, an analysis of trial data revealed a statistically significant increase in serious adverse events (SAEs) in the mRNA group. The FDA used pooled data from multiple trials to dilute this safety signal, despite acknowledging potential variations. Concerns also arise from higher mortality rates in mRNA groups across trials.

Merck and Moderna reported positive Phase 3 trial results for a personalized mRNA vaccine targeting melanoma, combined with Merck's Keytruda. The treatment improved recurrence-free survival, marking a potential first FDA-approved mRNA cancer therapy. The vaccine is customized using a patient's tumor DNA and RNA, teaching the immune system to target cancer cells. Costs and production time remain high, but experts anticipate advancements in manufacturing and AI-driven targeting.

Moderna and Merck's mRNA therapy intismeran, combined with KEYTRUDA, met Phase 3 trial endpoints for recurrence-free and distant-metastasis-free survival in high-risk melanoma patients. The trial enrolled 1,137 participants, but exact benefit sizes were not disclosed. The companies plan to present detailed data later. Intismeran is not yet available outside trials.

The FDA approved updated COVID-19 vaccines for the 2026-2027 season from Moderna, Pfizer, and Novavax-Sanofi, targeting the XFG subvariant. Pfizer's Comirnaty XFG, Moderna's SpikeVax and mNEXSPIKE, and Novavax-Sanofi's Nuvaxovid are approved for specific age groups and high-risk individuals. CDC recommendations from 2025-2026 remain in effect. Vaccines are available at pharmacies and healthcare centers, with coverage by insurers, Medicaid, and Medicare.